<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie Dukhovny, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynn L Simpson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neural tube defects (NTDs) are relatively common congenital anomalies that develop when a portion of the neural tube fails to close normally during the third and fourth weeks after conception (the fifth and sixth weeks of gestation). The resulting defect may involve the vertebrae, spinal cord, cranium, and/or brain. (See  <a class="medical medical_review" href="/d/html/6170.html" rel="external">"Myelomeningocele (spina bifida): Anatomy, clinical manifestations, and complications", section on 'Embryology of the neural tube'</a>.)</p><p>Two key advances related to NTDs have occurred in recent decades:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> fortification of commonly consumed foods (eg, bread, flour, cornmeal, rice, pasta) and administration of folic acid supplements have been shown to prevent occurrence/recurrence of most NTDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal serum and sonographic screening programs have led to identification of most affected pregnancies, allowing parents to make decisions about pregnancy management.</p><p></p><p>This topic will provide an overview of prenatal screening for and evaluation of NTDs, parental counseling, and pregnancy management. Sonographic diagnosis of NTDs and <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation for prevention of NTDs are discussed separately. (See  <a class="medical medical_review" href="/d/html/6831.html" rel="external">"Neural tube defects: Prenatal sonographic diagnosis"</a> and  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p>Pediatric management and prognosis for children with NTDs are also discussed separately. (See  <a class="medical medical_review" href="/d/html/6219.html" rel="external">"Myelomeningocele (spina bifida): Management and outcome"</a> and  <a class="medical medical_review" href="/d/html/6171.html" rel="external">"Primary (congenital) encephalocele"</a> and  <a class="medical medical_review" href="/d/html/16869.html" rel="external">"Anencephaly"</a>.)</p><p class="headingAnchor" id="H1944028399"><span class="h1">TYPES OF NEURAL TUBE DEFECTS</span><span class="headingEndMark"> — </span>NTDs may be open or closed. Open NTDs (defect is only covered by a membrane or, rarely, nothing at all) comprise 80 percent of NTDs; the most common are myelomeningocele (open spina bifida) and anencephaly. Open NTDs of the spine can be associated with cerebral ventriculomegaly. (See  <a class="medical medical_review" href="/d/html/6170.html" rel="external">"Myelomeningocele (spina bifida): Anatomy, clinical manifestations, and complications"</a> and  <a class="medical medical_review" href="/d/html/16869.html" rel="external">"Anencephaly"</a>.)</p><p>Examples of closed NTDs (defect is covered by skin) include lipomyelomeningocele and lipomeningocele. Although covered with skin, closed NTDs may be associated with a tuft of hair, dimple, birthmark, lump, or other skin abnormality at the site of the defect, as well as cerebral ventriculomegaly. Closed NTDs will not be discussed further in this topic, but are reviewed separately. (See  <a class="medical medical_review" href="/d/html/14405.html" rel="external">"Closed spinal dysraphism: Pathogenesis and types"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The prevalence of NTDs worldwide is highly variable. In a 2016 systematic review, NTD prevalence medians were: Eastern Mediterranean (21.9 per 10,000 births), Southeast Asia (15.8 per 10,000 births), Africa (11.7 per 10,000 births), Americas (11.5 per 10,000 births), Europe (9.0 per 10,000 births), and Western Pacific (6.9 per 10,000 births) [<a href="#rid1">1</a>]. In the United States, the prevalence was 5.5 to 6.5 per 10,000 live births from 2009 to 2011, the most recent available data [<a href="#rid2">2</a>].</p><p>These differences may reflect differences in genetic predisposition as well as environmental factors/application of interventions. Periconceptional <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation, food fortification with folic acid, and prenatal screening for NTDs combined with access to pregnancy termination have led to a dramatic decrease in the prevalence of NTDs at birth where these interventions are applied (eg, 83 percent of anencephaly and 63 percent of spina bifida affected pregnancies are terminated [<a href="#rid3">3</a>]). (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Evidence of efficacy'</a>.)</p><p>Differences in prevalence may also reflect differences in surveillance systems. Prevalence should include all NTD phenotypes and all pregnancy outcomes (live births, stillbirths, and terminations of pregnancy for fetal anomalies) to avoid underestimation [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H3731320678"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of NTDs is multifactorial, related to genetic, environmental, and autoimmune factors [<a href="#rid5">5</a>]. NTDs may result from an underlying abnormality of one or more of the pathways necessary to achieve neural tube closure or from a genetic variant or environmental insult that disrupts the closure process even when the underlying pathway is intact [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H7"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H1089579148"><span class="h2">Folate deficiency</span><span class="headingEndMark"> — </span>Most isolated NTDs appear to be caused by folate deficiency ("folate sensitive" NTDs), likely in combination with genetic or environmental risk factors [<a href="#rid7">7</a>]. </p><p>Folate deficiency may be related to inadequate oral intake, inadequate intestinal absorption, use of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> antagonists, or genetic factors and medications causing abnormal folate metabolism. Folic acid antagonists that have been linked to an increased risk of NTDs include <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid8">8-10</a>]. Some conditions that may be associated with malabsorption include inflammatory bowel disease and gastric bypass surgery. A gluten-free diet is a risk factor for inadequate oral intake. (See  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>.)</p><p>Several lines of evidence support the hypothesis of a link between folate and NTDs:</p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials have consistently shown that <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation markedly reduces the incidence of NTDs. Observational studies have reported substantial reductions in NTDs after legislation for initiation of food fortification with folic acid [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Evidence of efficacy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of specific <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> antagonists increases the risk of NTDs [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum and red cell folate concentrations are lower in patients carrying a child with an NTD or who had a previous pregnancy with an NTD than in those with unaffected pregnancies [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Methylenetetrahydrofolate reductase (<em>MTHFR)</em> is one of the enzymes that regulate the intracellular folate pool for synthesis and methylation of DNA. A common genetic polymorphism (677C-&gt;T) reduces its catalytic activity. Both heterozygous CT and homozygous TT genotypes are associated with a low tissue concentration of folate and a "dose" responsive increase in risk of NTDs. In a systematic review, compared with normal controls (CC), the odds of the CT and TT genotypes in patients with NTDs were 1.2 and 1.9, respectively [<a href="#rid17">17</a>]. Mothers with NTD progeny were also more likely to carry the CT and TT genotypes than CC controls (odds ratio [OR] 1.1 and 2.0, respectively).</p><p></p><p class="headingAnchor" id="H2100671721"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Although no specific genes have been identified, genetic factors have been implicated in the pathogenesis of NTDs because NTDs are highly concordant in monozygotic twins as compared with dizygotic twins [<a href="#rid18">18</a>], recur within families (1/20 recurrence risk with one previous affected pregnancy and 1/10 recurrence risk with two affected pregnancies) [<a href="#rid19">19</a>], and are more common in females than in males [<a href="#rid20">20</a>]. Genetic factors include polymorphisms that affect the efficiency of folate metabolism, DNA methylation/epigenetics, and chromosomal abnormalities [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H888226503"><span class="h2">Syndromes</span><span class="headingEndMark"> — </span>Syndromes that may be associated with NTDs include Meckel-Gruber, Roberts, Jarcho-Levin, HARD (hydrocephalus, agyria, and retinal dysplasia), trisomy 13 or 18, and triploidy. Limb-body wall complex, cloacal exstrophy, and OEIS complex (omphalocele, exstrophy of the cloaca, imperforate anus, and spine abnormalities) are also associated with NTDs.</p><p class="headingAnchor" id="H2853824966"><span class="h2">Amniotic band sequence</span><span class="headingEndMark"> — </span>Amniotic bands can physically disrupt normal neural tube development, resulting in NTDs. (See  <a class="medical medical_review" href="/d/html/6764.html" rel="external">"Amniotic band sequence"</a>.)</p><p class="headingAnchor" id="H2793547954"><span class="h2">Fever/hyperthermia</span><span class="headingEndMark"> — </span>Elevation of maternal core temperature from a febrile illness or other source (eg, hot tub, sauna) in the first trimester may be associated with an increased risk of congenital anomalies, especially NTDs, or miscarriage [<a href="#rid22">22-24</a>]. In a meta-analysis of 46 case-control and cohort studies of the effect of antepartum maternal fever on offspring, maternal fever was associated with increased risks of NTDs (OR 2.90, 95% CI 2.22-3.79, nine studies), congenital heart disease (OR 1.54, 95% CI 1.37-1.74, seven studies), and oral clefts (OR 1.94, 95% CI 1.35-2.79, five studies), but miscarriage rates were not increased [<a href="#rid25">25</a>]. The authors hypothesized that patients may have been recruited too late in pregnancy to identify those with early pregnancy losses given that animal studies and individual studies support an association [<a href="#rid23">23,26</a>].</p><p>Carefully performed prospective studies are needed as the studies in this meta-analysis had several limitations. For example, fever was ascertained by maternal self-report in all but one study and included episodes of fever from up to three months before conception. The degree and duration of fever were not consistently reported or accurately determined, and it is known from animal studies that the consequences of hyperthermia depend upon the extent of temperature elevation, its duration, and the stage of development at which it occurs [<a href="#rid23">23,27</a>]. Importantly, fever usually occurs as a response to infection, which necessitates distinguishing the effects of fever from those of an underlying infection and/or its treatment.</p><p>The association between hyperthermia and NTDs appears to be weaker for individuals who report consuming the recommended amount of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> (≥400 mcg per day: OR 1.8, 95% CI 0.8-4.0) than for those with low folic acid intake (&lt;400 mcg per day: OR 4.2, 95% CI 2.2-8.2) [<a href="#rid28">28</a>].</p><p>Antipyretic use also seems to attenuate the risks associated with fever exposure [<a href="#rid25">25</a>]. The National Birth Defects Prevention Study (NBDPS) observed that maternal fever from a cold or the flu during early pregnancy was associated with an increased risk for selected congenital anomalies [<a href="#rid29">29</a>] and, among pregnant people with infection-related fever, single-agent use of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> was associated with a statistically significant reduction in NTDs, as well as cleft lip/palate and gastroschisis [<a href="#rid30">30</a>]. The reduction in congenital anomalies should be confirmed in other studies before acetaminophen is recommended to febrile pregnant people only for this purpose. (See  <a class="medical medical_review" href="/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Acetaminophen'</a>.)</p><p class="headingAnchor" id="H707373226"><span class="h2">Pregestational diabetes</span><span class="headingEndMark"> — </span>Poorly controlled pregestational (preexisting) diabetes mellitus (type 1 or type 2) has been associated with NTDs  (<a class="graphic graphic_table graphicRef108112" href="/d/graphic/108112.html" rel="external">table 1</a>) [<a href="#rid31">31-34</a>]. Good periconceptional glucose control is the key factor for preventing NTDs and other anomalies in these pregnancies, but <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> also plays a role. A particular challenge is the increased frequency of type 2 diabetes that is unrecognized by the patient before they are screened during pregnancy. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Preexisting diabetes'</a>.)</p><p class="headingAnchor" id="H1367488333"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>Pregnant individuals with obesity have an almost twofold increase in risk of NTDs. This is particularly a concern because of the limitations of fetal imaging as the mother's body mass index increases [<a href="#rid35">35</a>]. Increased <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation does not appear to decrease the recurrence or occurrence rate of NTDs related to obesity. (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Congenital anomalies'</a>.)</p><p class="headingAnchor" id="H3299703239"><span class="h2">Other possible risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pesticide exposure</strong> – Studies evaluating maternal pesticide exposure have not demonstrated an association between pesticide exposure and NTDs [<a href="#rid36">36</a>]. Studies also have not demonstrated an association between paternal pesticide exposures and NTDs; however, a weak association has been observed when there is both maternal and paternal exposure [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrosatable drugs and </strong><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> – Associations between use of nitrosatable drugs (eg, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>) and NTDs have been reported [<a href="#rid38">38</a>]. The potential for bias and lack of information about underlying health disorders leading to use of nitrosatable drugs preclude drawing strong conclusions from these studies.</p><p></p><p class="bulletIndent1">In a meta-analysis, periconceptional exposure to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate was not associated with a clear increase in risk of NTDs (pooled OR 1.21, 95% CI 0.88-1.66 [<a href="#rid39">39</a>]). The inability to assess the independent effects of subfertility precludes drawing strong conclusions from available studies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dolutegravir</strong><strong> </strong>– Surveillance data from Botswana have suggested a potential association between maternal <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> use at the time of conception and NTDs in offspring, but the absolute risk remains small [<a href="#rid40">40,41</a>]. In the United States from 2013 to 2017, the NTD prevalence in pregnancies of mothers with HIV was similar to that in the general obstetric population [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/3753.html" rel="external">"HIV and women", section on 'Individuals of childbearing potential'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary factors</strong> – A variety of dietary factors other than folate deficiency have been associated with NTDs, but require further study [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">PRENATAL SCREENING AND DIAGNOSIS</span></p><p class="headingAnchor" id="H364642121"><span class="h2">Burden of disease</span><span class="headingEndMark"> — </span>NTDs result in substantial morbidity and mortality: Anencephaly is almost always lethal in utero or within hours or days of birth; encephalocele is often lethal or results in severe neurologic and cognitive deficits; spina bifida can cause varying degrees of neurologic impairment, depending upon the level of the lesion, and can impair cognitive function, depending upon the presence and degree of associated ventriculomegaly or associated genetic syndrome.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16869.html" rel="external">"Anencephaly"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6171.html" rel="external">"Primary (congenital) encephalocele"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6170.html" rel="external">"Myelomeningocele (spina bifida): Anatomy, clinical manifestations, and complications"</a>.)</p><p></p><p class="headingAnchor" id="H2115402922"><span class="h2">Rationale for prenatal screening</span><span class="headingEndMark"> — </span>Screening and early diagnosis of affected pregnancies allows the parent(s) the option of pregnancy termination, consideration of in utero repair, or an opportunity to prepare for the birth of an affected child. Prenatal detection of an NTD can also inform decisions about the optimal time, route, and site of birth. (See <a class="local">'Postdiagnostic fetal evaluation'</a> below.)</p><p class="headingAnchor" id="H606090982"><span class="h2">Candidates for screening</span><span class="headingEndMark"> — </span>All pregnant people should be offered screening for NTDs as universal screening identifies the majority of affected pregnancies [<a href="#rid44">44,45</a>] (see <a class="local">'Screening tests'</a> below). Selective screening based on risk factors performs poorly since 90 to 95 percent of cases occur in pregnancies without any risk factors [<a href="#rid46">46</a>].</p><p>In the United States, universal screening is supported by the American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid47">47</a>] and the American College of Medical Genetics and Genomics (ACMG) [<a href="#rid48">48</a>]. These organizations emphasize the need to provide adequate counseling and follow-up services, expertise in high-resolution ultrasound and detection of fetal anomalies, capability for amniocentesis for further fetal evaluation (if needed), and reliable standardized laboratories.</p><p class="headingAnchor" id="H606090976"><span class="h2">Additional benefits and risks of screening</span><span class="headingEndMark"> — </span>Screening for NTDs may lead to detection of fetal abnormalities other than NTDs [<a href="#rid49">49,50</a>]. Sonographic screening for NTDs may detect other congenital anomalies. Maternal serum screening may lead to detection of fetuses with congenital nephrosis, some types of abdominal wall defects, and some tumors associated with elevated alpha-fetoprotein levels. (See <a class="local">'Alpha-fetoprotein'</a> below.)</p><p>The risks of screening include the anxiety associated with positive results and complications associated with postscreening interventions, such as invasive procedures, if performed.</p><p class="headingAnchor" id="H606090749"><span class="h2">Screening tests</span><span class="headingEndMark"> — </span>The two approaches to NTD screening are ultrasound examination and measurement of maternal serum alpha-fetoprotein (MSAFP).</p><p class="headingAnchor" id="H1869105300"><span class="h3">Choice of test</span><span class="headingEndMark"> — </span>We suggest ultrasound screening for NTDs as long as high-quality second-trimester fetal ultrasound is available because it appears to detect more NTDs than MSAFP alone [<a href="#rid51">51</a>]. (See <a class="local">'NTD detection rate'</a> below and <a class="local">'Ultrasound examination'</a> below.)</p><p>When ultrasound screening is performed to detect NTDs, we believe MSAFP screening is not required. However, if optimal images of the fetal spine or intracranial anatomy are not obtained (eg, fetal position or maternal obesity), MSAFP should be performed to improve detection of NTDs.</p><p>ACOG states that high-quality, second-trimester fetal anatomy ultrasonography is an appropriate screening test for NTDs where routinely performed for fetal anatomic survey at 18 to 22 weeks [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H606091073"><span class="h3">Ultrasound examination</span><span class="headingEndMark"> — </span>NTDs involve the spine, and often the cerebral ventricles and cranium. The diagnostic findings on ultrasound examination (including multiple graphic images) are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6831.html" rel="external">"Neural tube defects: Prenatal sonographic diagnosis"</a>.)</p><p class="headingAnchor" id="H3559490741"><span class="h4">Timing</span><span class="headingEndMark"> — </span>If two ultrasound examinations are planned as part of routine prenatal care in the first half of pregnancy, experts generally suggest performing the first study transvaginally at 11 to 14 weeks of gestation and the second examination transabdominally at 18 to 20 weeks of gestation. If one ultrasound examination is planned, the optimal timing is at 18 to 20 weeks of gestation. This allows for good visualization of anatomy and is sufficiently early to allow completion of prenatal diagnostic procedures (eg, amniocentesis for chromosomal microarray, additional imaging studies) at a gestational age below which pregnancy termination may be permitted. If pregnancy termination is desired, clinicians should be aware of the laws in their state and nearby regions regulating the upper gestational age for termination of pregnancy. </p><p class="headingAnchor" id="H1997380303"><span class="h4">NTD detection rate</span><span class="headingEndMark"> — </span>First-trimester studies at 11 to 14 weeks of gestation using transvaginal ultrasound generally have reported detection rates &gt;90 percent for anencephaly and 80 percent for encephalocele but lower rates for spina bifida (44 percent). By comparison, a review of second-trimester ultrasound examination in a high-risk population reported 92 to 95 percent detection of spina bifida and 100 percent detection of anencephaly [<a href="#rid52">52</a>]. Thus, second-trimester ultrasound examination needs to be performed if the first-trimester examination is normal.</p><p>Detection of NTDs on ultrasound examination depends in part upon the size and location of the defect, the position of the fetus, the volume of amniotic fluid, maternal habitus (maternal obesity decreases detection rates [<a href="#rid35">35</a>]), and the skill and equipment of the sonographer/sonologist.</p><p class="headingAnchor" id="H14"><span class="h3">Alpha-fetoprotein</span><span class="headingEndMark"> — </span>Alpha-fetoprotein (AFP) is a fetal-specific globulin, synthesized by the fetal yolk sac, gastrointestinal tract, and liver. Its function is unknown. Maternal serum screening (MSAFP) is performed ideally at 16 to 18 weeks of gestation but can be performed as early as 15 weeks or as late as 20 weeks [<a href="#rid48">48</a>]. First-trimester serum screening is not recommended because of low sensitivity [<a href="#rid53">53-57</a>].</p><p>Results are expressed as multiples of the median (MoM) for each gestational week because these values are easy to derive, stable, and allow for interlaboratory variation. A value ≥2.0 or 2.5 MoM is considered an abnormal result, depending upon the laboratory's preference for balancing the detection and false-positive rates in their population.</p><p>Many factors influence the correct interpretation of MSAFP results:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gestational age</strong> – Accurate estimation of gestational age is critical to interpretation of MSAFP. An incorrect gestational age will falsely raise or lower the reported MoM, since it is based upon gestational age. (See  <a class="medical medical_review" href="/d/html/5391.html" rel="external">"Prenatal assessment of gestational age, date of delivery, and fetal weight"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal weight</strong> – Maternal weight should be measured and reported to the MSAFP laboratory on the day of testing.</p><p class="bulletIndent1">Maternal weight affects MSAFP screening because of dilution of AFP in the larger blood volume of heavier individuals. Correction for maternal weight increases the detection rate for NTDs [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes mellitus</strong> – The presence of maternal diabetes should always be noted on the MSAFP laboratory requisition.</p><p class="bulletIndent1">The prevalence of NTDs is higher in pregnant individuals with pregestational diabetes mellitus. In addition, the MSAFP level in pregnant individuals with type 1 diabetes is 15 percent lower than in pregnant individuals without diabetes. For these reasons, there is a lower threshold MSAFP value (eg, approximately 1.5 MoM) to obtain the same sensitivity for detection of NTDs as in individuals without diabetes. MSAFP levels for individuals with type 2 diabetes are also lower, although the data in this setting are more limited [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal anomalies</strong> – Non-NTD fetal anomalies can be associated with an elevated MSAFP. There is direct correlation between the degree of MSAFP elevation and the frequency of anomalies. In one study, the risk was 3 percent at a level of 2.5 MoMs and 40 percent at a level &gt;7.0 MoMs [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Abdominal wall anomalies are commonly associated with elevated MSAFP levels. One representative series reported MSAFP was raised in 89 percent of fetuses with omphalocele and in 100 percent of fetuses with gastroschisis [<a href="#rid61">61</a>]. Fetal congenital nephrosis, teratomas, benign obstructive uropathy, and fetal anemia can also be associated with elevated MSAFP levels. (See  <a class="medical medical_review" href="/d/html/6137.html" rel="external">"Congenital nephrotic syndrome"</a> and  <a class="medical medical_review" href="/d/html/6753.html" rel="external">"Gastroschisis"</a> and  <a class="medical medical_review" href="/d/html/6763.html" rel="external">"Omphalocele: Prenatal diagnosis and pregnancy management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple gestation</strong> – The concentration of MSAFP is proportional to the number of fetuses; thus, the upper limit for a twin pregnancy is twice (eg, 4 to 5 MoMs) that of a singleton gestation. Multiple gestations are also at slightly increased risk for NTDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race</strong> – As NTDs are less common in the pregnancies of Black individuals (approximately half the incidence compared with White individuals), a higher MSAFP cutoff (2.5 MoM versus 2.0 MoM) has been used to decrease false-positive rates [<a href="#rid62">62</a>]. As a result, screening for NTDs among Black individuals may not have the same detection rate as when performed in White individuals. Using a different cutoff in Black individuals has been challenged since race is a social construct and prior research suggesting the appropriateness of a different cut-off may have been flawed. Review of these data has suggested there is no difference in MSAFP values between Black and non-Black pregnant individuals when adjusted by maternal weight and gestational age at blood draw [<a href="#rid63">63</a>]. Review of these data suggests MSAFP values for Black and non-Black pregnant individuals are similar when adjusted by maternal weight and gestational age at blood draw. We agree that race-based adjustment of MSAFP values for Black individuals should be abandoned. We also agree that further research should be performed to determine how the removal of race adjustment might change test performance characteristics and subsequent rates of diagnostic testing [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1">An American College of Medical Genetics Technical Bulletin on MSAFP screening advises adjustment for maternal Black race and the College of American Pathologists requires laboratories that perform maternal prenatal serum screening to ask about race to enable race-specific adjustments for maternal AFP [<a href="#rid64">64,65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal viability</strong> – Fetal death raises the MSAFP value. In cases of multiple gestation with death of one fetus, MSAFP results are not interpretable for this reason.</p><p></p><p class="headingAnchor" id="H4055020500"><span class="h4">NTD detection rate</span><span class="headingEndMark"> — </span>ACMG reported the detection rate for anencephaly is ≥95 percent at 2.0 or 2.5 MoMs [<a href="#rid62">62</a>]. For open spina bifida, the detection rate at 2.0 MoMs is 75 to 90 percent versus 65 to 80 percent at 2.5 MoMs, with false-positive rates of 2 to 5 percent and 1 to 3 percent, respectively.</p><p>A meta-analysis of effectiveness of prenatal serum biomarker screening for NTDs reported overall sensitivity and specificity of 75.1 and 97.7 percent, respectively, and a false-positive rate of 2.2 percent and false-negative rate of 24.9 percent (22 studies, 684,112 participants) [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H1902864778"><span class="h4">Follow-up of screen-positive MSAFP results</span><span class="headingEndMark"> — </span>An ultrasound examination is performed to further assess whether an NTD or another anomaly associated with elevated MSAFP levels is present, as well as to confirm gestational age, fetal viability, and number of fetuses. All of these factors can affect interpretation of MSAFP results. (See <a class="local">'Ultrasound examination'</a> above and <a class="local">'Alpha-fetoprotein'</a> above.)</p><p>An unexplained elevated MSAFP may be a marker for pregnancies at increased risk of some complications (eg, early fetal demise, fetal growth restriction, preeclampsia); however, the predictive value of MSAFP alone is low, and evidence does not support any outcome benefit from more intensive fetal and maternal monitoring in otherwise normal pregnancies [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H2264950962"><span class="h1">PARENTAL COUNSELING AND REFERRALS</span><span class="headingEndMark"> — </span>After sonographic diagnosis of an NTD, parents are faced with the choice of preparing for the birth of an affected child, considering in utero intervention, or pregnancy termination. Additional fetal evaluation to detect associated anatomic or chromosomal abnormalities; referral to a spina bifida clinic to discuss possible fetal interventions, postnatal management, and prognosis; and facilitating a connection with other parents of affected children to discuss what to expect for their child and family can help them make this decision. (See  <a class="medical medical_review" href="/d/html/6219.html" rel="external">"Myelomeningocele (spina bifida): Management and outcome", section on 'Prenatal counseling and choice of management'</a>.)</p><p>Prolonged exposure of neural tissue to neurotoxic amniotic fluid, microtrauma at the level of the exposed neural elements, and continuous leakage of cerebrospinal fluid may result in progressive development of fetal hydrocephalus and loss of nerve function. Postnatally, this can result in musculoskeletal weakness and bowel and genitourinary dysfunction. In utero determination of the upper anatomic level of the spinal defect (L1, L2, L3, L4, L5, S1) and fetal motor activity allow some prediction of postnatal motor dysfunction; however, motor function will be accurately predicted by imaging in only 25 percent of infants, approximately 20 percent will perform one or more levels better than predicted, and approximately 50 percent will perform one or more levels worse than predicted [<a href="#rid67">67</a>]. This is because ultrasound assessment of lesion level is not precise [<a href="#rid68">68</a>], and more importantly, NTD is a heterogeneous group of conditions with outcomes depending on several factors in addition to lesion level, such as whether a sac is present, the role of a teratogenic agent and that agent's other effects (teratogenic medications, etc), and whether there is an underlying genetic etiology (not necessarily syndromic but detectable by sequencing).</p><p class="headingAnchor" id="H25"><span class="h1">POSTDIAGNOSTIC FETAL EVALUATION</span></p><p class="headingAnchor" id="H1645236876"><span class="h2">Screen for associated anomalies</span><span class="headingEndMark"> — </span>A complete fetal anatomic survey should be performed to look for associated anomalies, which occurred in 20 percent of the cases in one large series [<a href="#rid69">69</a>]. Oral clefts and malformations in the musculoskeletal, renal, and cardiovascular systems were the most common associated anomalies.</p><p class="headingAnchor" id="H487523366"><span class="h2">Offer chromosomal microarray</span><span class="headingEndMark"> — </span>Fetuses with NTDs are at increased risk of chromosomal abnormalities, especially if other anomalies are present [<a href="#rid70">70-76</a>]. As an example, a study evaluating the frequency of karyotype abnormalities in 200 fetuses with NTDs reported the overall frequency of chromosomal abnormalities was 6.5 percent, but was 2.4 percent in those with a referral diagnosis of isolated NTD and 27 percent in those with an NTD plus associated anomalies [<a href="#rid70">70</a>].</p><p>A discussion of further fetal genetic testing is appropriate. This information may impact pregnancy care, care after birth, and recurrence counseling. Although many NTDs are associated with genetic abnormalities that would be detected by a conventional G-banded karyotype, microarray has become the preferred genetic test when structural abnormalities are identified given the additional yield of pathogenic subchromosomal copy number variants. (See  <a class="medical medical_review" href="/d/html/104101.html" rel="external">"Prenatal genetic evaluation of the fetus with anomalies or soft markers"</a>.)</p><p class="headingAnchor" id="H364653181"><span class="h2">Role of gene sequencing</span><span class="headingEndMark"> — </span>We suggest prenatal sequencing only in collaboration with a prenatal diagnostic program with expertise in genomic testing and interpretation of such data. Gene sequencing, including exome and genomic sequencing, is increasingly being utilized in prenatal clinics. Two large studies indicate that the presence of a structural anomaly confers an approximate 6 to 10 percent risk of a pathogenic variant in the fetus's gene sequence [<a href="#rid77">77,78</a>]. Prenatal clinical exome sequencing, such as is used in the neonatal care unit and pediatric setting, is likely to become available. </p><p>Interpretation of the results requires close collaboration between the imaging provider, laboratory, and geneticist. Variants of unknown significance remain a diagnostic challenge, especially in the prenatal setting, where time to results is critical and a detailed phenotype is impeded by the in utero status. </p><p class="headingAnchor" id="H4080914129"><span class="h2">Consider fetal magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is not performed routinely but may be done in selected cases, such as to confirm uncertain ultrasound findings and exclude/detect central nervous system and other abnormalities when this information will affect pregnancy management. In particular, confirming the absence of additional major structural anomalies is one of the key factors in determining whether the second-trimester fetus is an appropriate candidate for in utero fetal surgery. (See  <a class="medical medical_review" href="/d/html/140435.html" rel="external">"Open spina bifida: In utero treatment and delivery considerations"</a>.)</p><p>MRI is also sometimes performed to better define the level of the NTD, although this does not correlate well with postnatal motor function) [<a href="#rid79">79</a>]. (See <a class="local">'Parental counseling and referrals'</a> above.)</p><p>In a study that evaluated the role of MRI in 19 fetuses with ultrasound findings suspicious for NTDs and in whom the ultrasound examination was deemed to be inadequate, fetal MRI correctly ruled out the ultrasound diagnosis of cephalocele in one fetus with oligohydramnios and documented an NTD in the other 18 fetuses [<a href="#rid80">80</a>]. Fetal MRI also detected new findings unsuspected at ultrasound that changed the ultrasound diagnosis in 3 of the 19 cases and detected previously occult findings that caused a minor change in the classification of the anomaly in 5 of the 19 cases. MRI did not influence the ultrasound diagnosis in the other 11 of 19 fetuses.</p><p class="headingAnchor" id="H1276364078"><span class="h1">PREGNANCY MANAGEMENT</span></p><p class="headingAnchor" id="H1669142009"><span class="h2">Consider fetal surgery for myelomeningocele repair</span><span class="headingEndMark"> — </span>Fetal surgery for myelomeningocele repair arrests leakage of spinal fluid from the back and might, therefore, prevent or reverse herniation of the hindbrain (Chiari II malformation) and hydrocephalus and their adverse sequelae. It is a complex procedure that should be performed at a fetal surgery center with the requisite expertise. Candidates for fetal surgery, counseling, techniques, and outcomes are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/140435.html" rel="external">"Open spina bifida: In utero treatment and delivery considerations"</a>.)</p><p class="headingAnchor" id="H4248433917"><span class="h2">Fetal surveillance</span></p><p class="bulletIndent1"><span class="glyph">●</span>Serial ultrasound examinations to assess the size of the fetal head, appearance of associated Chiari malformation, the size of the ventricles, and the size of the NTD can inform birth planning of potentially viable neonates [<a href="#rid81">81</a>]. The optimum frequency is unclear, but monthly examinations until birth are reasonable.</p><p></p><p class="bulletIndent1">While marked ventriculomegaly is not common with NTD, when the biparietal diameter is &gt;99 percentile, then a vaginal birth would be contraindicated and discussion of a classical cesarean is appropriate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For fetuses who underwent in utero repair of the NTD, follow-up imaging (ultrasound, magnetic resonance imaging) is guided by the protocol of the center that performed the procedure. The imaging examination should also evaluate the uterine wall.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because fetuses with major congenital anomalies appear to be at increased risk of stillbirth [<a href="#rid82">82</a>], some clinicians, including the authors of this topic, monitor pregnancies with NTDs with nonstress tests or biophysical profiles after 34 weeks. No evidence is available to support or refute the value of this approach. Typically, fetuses with an NTD remain active; however, the quality of fetal movement is often different from that in normal fetuses [<a href="#rid83">83-87</a>] and they may not respond to vibroacoustic stimulation [<a href="#rid88">88,89</a>]. (See  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p></p><p class="headingAnchor" id="H686257428"><span class="h2">Delivery</span></p><p class="headingAnchor" id="H3309506409"><span class="h3">Myelomeningocele</span></p><p class="headingAnchor" id="H3853116894"><span class="h4">Preparation</span><span class="headingEndMark"> — </span>For neonates with a prenatal diagnosis of myelomeningocele, birth should occur at a center with a level III or above neonatal intensive care unit, pediatric neurosurgery services, and other personnel experienced in the neonatal management of these infants. Ideally, latex-free gloves and equipment are used during the birth and subsequent care of the newborn because individuals with myelomeningocele are at risk for developing life-threatening latex allergy later in life [<a href="#rid90">90,91</a>].</p><p class="headingAnchor" id="H3664646184"><span class="h4">Timing</span><span class="headingEndMark"> — </span>Term birth is preferable to minimize preterm birth-related morbidity. If in utero surgery with transfundal surgical repair of the NTD was performed, early term or late preterm cesarean birth is indicated because of the increased risk of uterine rupture during labor. In our practice, this is often determined by whether the patient is experiencing late preterm ongoing contractions.</p><p class="headingAnchor" id="H1214542712"><span class="h4">Route</span><span class="headingEndMark"> — </span>Fetuses presenting in the breech position are typically delivered by cesarean. No randomized trials have been performed to determine the risks and benefits of labor and vaginal birth for cephalic-presenting fetuses in the absence of standard indications for cesarean birth. Although the first retrospective study to evaluate motor outcome by route of birth reported a benefit from prelabor cesarean [<a href="#rid92">92</a>], the body of data from subsequent observational studies has not confirmed this association. </p><p class="bulletIndent1"><span class="glyph">●</span>In a 2019 meta-analysis of nine studies (one prospective and eight retrospective cohort studies, 672 participants) comparing vaginal and cesarean birth in pregnancies that did not undergo fetal repair of NTDs, the motor-anatomic level in offspring was similar for both groups (mean difference -0.10, 95% CI -0.58 to 0.38), and the vaginal birth group was less likely to require a shunt or have sac disruption (odds ratio [OR] 0.37, 95% CI 0.14-0.95 and OR 0.46, 95% CI 0.23-0.90, respectively) [<a href="#rid93">93</a>]. Prelabor cesarean was associated with a nonstatistically significant trend toward improved ambulation in toddlers compared with exposure to labor (ie, vaginal birth or intrapartum cesarean [ambulation, independent or with assistance, at age two years with prelabor cesarean: OR 2.13, 95% CI 0.35-13.12]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent 2019 retrospective study including nearly 2000 nonsyndromic, liveborn neonates with spina bifida, cesarean birth was not associated with a significant reduction in risk of infant death (cesarean versus vaginal birth: hazard ratio [HR] for death before 29 days 0.77, 95% CI 0.49-1.21 and HR for death before 365 days 0.93, 95% CI 0.63-1.38, respectively) [<a href="#rid94">94</a>].</p><p></p><p>In the absence of data establishing a benefit of prelabor cesarean birth for fetuses with myelomeningocele, we believe mode of delivery should involve shared decision-making between the pregnant person and the obstetrician. However, data regarding the role of nonlabored cesarean birth on ambulation continues to emerge and should be reviewed with the patient.</p><p>Vaginal birth is reasonable if the head is near normal size, the meningocele is unlikely to cause dystocia, and no obstetric indications for cesarean birth are present. Cesarean birth is indicated in cases in which the head circumference (HC) is increased, and vaginal birth is thought to be not possible because of dystocia. The cutoff for determining when a cesarean birth is indicated will vary with gestational age at birth, the absolute and relative HC, and the size of the maternal pelvis. We believe that abdominal birth to avoid cephalopelvic disproportion is reasonable when the HC is &gt;40 cm or the biparietal diameter is ≥12 cm. Pelvimetry is unlikely to be of benefit and is generally not used in this setting. </p><p class="headingAnchor" id="H3779201121"><span class="h3">Anencephaly</span><span class="headingEndMark"> — </span>Most anencephalic fetuses are stillborn or die shortly after birth, but some newborns have been reported to survive as long as 28 days [<a href="#rid95">95,96</a>]. Given this poor prognosis, most pregnancies are terminated. </p><p>In ongoing pregnancies, maternal morbidity is increased compared with pregnancies not affected by anencephaly [<a href="#rid97">97</a>]. Preterm labor and birth may occur from uterine overdistention due to polyhydramnios or the pregnancy may extend postterm because absence of fetal brain precludes normal pathways in fetal initiation of labor [<a href="#rid98">98</a>]. Cesarean birth is only performed for maternal indications [<a href="#rid99">99,100</a>]. </p><p>Anencephalic neonates are not good candidates for organ donation. (See  <a class="medical medical_review" href="/d/html/16869.html" rel="external">"Anencephaly", section on 'Postnatal management'</a>.)</p><p class="headingAnchor" id="H1004872848"><span class="h3">Encephalocele</span><span class="headingEndMark"> — </span>No data are available on outcomes with vaginal versus cesarean birth. The mode of birth should take into account the postnatal prognosis. For viable neonates, vaginal birth may be safe if the lesion is relatively small and appears unlikely to cause dystocia or become traumatized, whereas cesarean birth is prudent if the encephalocele is large. These are subjective clinical judgments based on shared decision-making among the obstetric providers, parents, neonatologists, and pediatric neurosurgeons.</p><p class="headingAnchor" id="H540385075"><span class="h1">RECURRENCE RISK</span></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of recurrence for isolated NTDs is approximately 2 to 4 percent with one affected sibling [<a href="#rid101">101-105</a>]. With two affected siblings, the risk is approximately 10 percent [<a href="#rid106">106</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of NTD according to family history is shown in the table  (<a class="graphic graphic_table graphicRef63266" href="/d/graphic/63266.html" rel="external">table 2</a>). The risk of recurrence appears to be higher in countries such as Ireland where the occurrence (prevalence) of NTDs is high [<a href="#rid107">107</a>]. Recurrence is likely related to a multifactorial inheritance pattern, including genetic and environmental risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The recurrence risk for anencephaly is estimated at 2 to 5 percent [<a href="#rid108">108</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated encephaloceles are not familial; however, encephaloceles may be part of specific genetic syndromes if there are associated anomalies; the inheritance pattern is autosomal recessive in these cases. As an example, the risk of recurrence for an encephalocele with Meckel-Gruber syndrome (posterior encephalocele, cleft palate, and polydactyly) is 25 percent in cases with known autosomal recessive inheritance.</p><p></p><p class="headingAnchor" id="H27"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Supplemental <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> is a safe and effective treatment for prevention of NTDs. Doses and administration are described in detail separately. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p>Testing for <em>MTHFR</em> polymorphisms is <strong>not</strong> recommended as routine <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation at 0.4 mg/day will adequately increase red cell and serum folate concentrations whether or not the patient has a polymorphism. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Populations in which higher folic acid dose is unlikely to reduce NTD risk'</a>.)</p><p class="headingAnchor" id="H1663349678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118927.html" rel="external">"Society guideline links: Congenital malformations of the central nervous system"</a> and  <a class="medical medical_society_guidelines" href="/d/html/123103.html" rel="external">"Society guideline links: Ultrasound imaging in pregnancy"</a>.)</p><p class="headingAnchor" id="H528792449"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87049.html" rel="external">"Patient education: Spina bifida (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Open neural tube defects (NTDs) are those in which the defect is only covered by a membrane or, rarely, nothing at all. Open NTDs comprise 80 percent of NTDs; the most common open NTDs are myelomeningocele (open spina bifida) and anencephaly. (See <a class="local">'Types of neural tube defects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most isolated NTDs appear to be caused by folate deficiency, likely in combination with genetic or other environmental risk factors. (See <a class="local">'Folate deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NTDs have also been associated with some genetic syndromes, amniotic band sequence, hyperthermia in early pregnancy, pregestational diabetes (including type 2), and obesity. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Candidates</strong> – All pregnant people should be offered screening for NTDs. Screening and early diagnosis of affected pregnancies allow the parent(s) the option of pregnancy termination or an opportunity to prepare for the birth of an affected child. Fetal surgery may be an option in some cases. (See <a class="local">'Candidates for screening'</a> above and <a class="local">'Rationale for prenatal screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ultrasound</strong> – We perform ultrasound screening for NTDs (ideally at 18 to 20 weeks) because it appears to detect more NTDs than maternal serum alpha-fetoprotein (MSAFP) screening. If optimal images of the fetal spine or intracranial anatomy are not obtained (eg, fetal position or maternal obesity) or high-quality ultrasound examination is unavailable, MSAFP screening should be offered. (See <a class="local">'Choice of test'</a> above and <a class="local">'Ultrasound examination'</a> above.)</p><p></p><p class="bulletIndent2">In a high-risk population, ultrasound examination has been reported to detect 92 to 95 percent of spina bifida and 100 percent of anencephaly. Detection of NTDs on ultrasound examination depends upon the size and location of the defect, the position of the fetus, the volume of amniotic fluid, maternal habitus (maternal obesity decreases detection rates), and the skill and equipment of the sonographer/sonologist. (See <a class="local">'Ultrasound examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MSAFP</strong> – For MSAFP screening, the American College of Medical Genetics and Genomics reports the detection rate for anencephaly is ≥95 percent at 2.0 or 2.5 multiples of the median (MoMs). For open spina bifida, the detection rate at 2.0 MoMs is 75 to 90 percent versus 65 to 80 percent at 2.5 MoMs, with false-positive rates of 2 to 5 percent and 1 to 3 percent, respectively. (See <a class="local">'NTD detection rate'</a> above.)</p><p></p><p class="bulletIndent2">In patients with an elevated MSAFP, an ultrasound examination is performed to further assess whether an NTD or another anomaly associated with elevated MSAFP levels is present, as well as to confirm gestational age, fetal viability, and number of fetuses. (See <a class="local">'Follow-up of screen-positive MSAFP results'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy management</strong> – When an NTD is detected on ultrasound examination, the obstetric provider should (see <a class="local">'Postdiagnostic fetal evaluation'</a> above and <a class="local">'Parental counseling and referrals'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Document for presence or absence of associated fetal abnormalities, including magnetic resonance imaging when needed to confirm uncertain ultrasound findings or better define the level of the NTD, and to exclude/detect central nervous system abnormalities.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Offer microarray because of the increased incidence of chromosomal abnormalities. Gene sequencing remains investigational but is actively evolving in clinical prenatal practice.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discuss reproductive options: pregnancy termination or continuation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Refer parents to a spina bifida clinic to discuss postnatal management, possible interventions, and prognosis. Also facilitate a connection with other parents of affected children.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discuss referral for fetal surgery for myelomeningocele. (See  <a class="medical medical_review" href="/d/html/140435.html" rel="external">"Open spina bifida: In utero treatment and delivery considerations"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serial ultrasound examinations are performed to assess the size of the fetal head, appearance of associated Chiari malformation, and the size of the ventricles. This information can inform delivery planning if marked head enlargement is present. The optimum frequency is unclear, but monthly examinations until delivery are reasonable. We also obtain nonstress tests after 34 weeks. (See <a class="local">'Fetal surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Birth</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Location</strong> – Birth should occur at term at a center with a level III or above neonatal intensive care unit, pediatric neurosurgery services, and other personnel experienced in the neonatal management of these infants. Ideally, latex-free gloves and equipment are used during delivery and subsequent care of the infant. (See <a class="local">'Myelomeningocele'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Route</strong> – Because no study has definitively shown advantages of cesarean birth for fetuses with myelomeningocele, we believe vaginal birth is reasonable if the head is near normal size, the meningocele is unlikely to cause dystocia, and there are no obstetric indications for cesarean. Cesarean delivery is indicated in cases in which the head circumference (HC) is increased, and vaginal delivery is thought not to be possible because of dystocia. The cutoff for determining when a cesarean delivery is indicated will vary with gestational age at delivery, the absolute and relative HC and the size of the maternal pelvis. Abdominal delivery to avoid cephalopelvic disproportion is reasonable when the HC is &gt;40 cm or the biparietal diameter is ≥12 cm. (See <a class="local">'Myelomeningocele'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of recurrence</strong> – The risk of recurrent NTDs according to family history is illustrated in the table  (<a class="graphic graphic_table graphicRef63266" href="/d/graphic/63266.html" rel="external">table 2</a>). (See <a class="local">'Recurrence risk'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENTS</strong> — The UpToDate editorial staff acknowledges Lauri Hochberg, MD, and Joanne Stone, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zaganjor I, Sekkarie A, Tsang BL, et al. Describing the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review. PLoS One 2016; 11:e0151586.</a></li><li><a class="nounderline abstract_t">Williams J, Mai CT, Mulinare J, et al. Updated estimates of neural tube defects prevented by mandatory folic Acid fortification - United States, 1995-2011. MMWR Morb Mortal Wkly Rep 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Johnson CY, Honein MA, Dana Flanders W, et al. Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: a systematic review of the literature. Birth Defects Res A Clin Mol Teratol 2012; 94:857.</a></li><li><a class="nounderline abstract_t">Kancherla V, Carmichael SL, Feldkamp ML, Berry RJ. Teratology society position statement on surveillance and prevalence estimation of neural tube defects. Birth Defects Res 2019; 111:5.</a></li><li><a class="nounderline abstract_t">Wilson RD, O'Connor DL. Maternal folic acid and multivitamin supplementation: International clinical evidence with considerations for the prevention of folate-sensitive birth defects. Prev Med Rep 2021; 24:101617.</a></li><li><a class="nounderline abstract_t">Greene ND, Copp AJ. Neural tube defects. Annu Rev Neurosci 2014; 37:221.</a></li><li><a class="nounderline abstract_t">Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol 2013; 12:799.</a></li><li><a class="nounderline abstract_t">Wen SW, Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can 2004; 26:475.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153:961.</a></li><li><a class="nounderline abstract_t">Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 2006; 22:214.</a></li><li><a class="nounderline abstract_t">Atta CA, Fiest KM, Frolkis AD, et al. Global Birth Prevalence of Spina Bifida by Folic Acid Fortification Status: A Systematic Review and Meta-Analysis. Am J Public Health 2016; 106:e24.</a></li><li><a class="nounderline abstract_t">Shlobin NA, LoPresti MA, Du RY, Lam S. Folate fortification and supplementation in prevention of folate-sensitive neural tube defects: a systematic review of policy. J Neurosurg Pediatr 2020; 27:294.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.</a></li><li><a class="nounderline abstract_t">Wald NJ, Hackshaw AD, Stone R, Sourial NA. Blood folic acid and vitamin B12 in relation to neural tube defects. Br J Obstet Gynaecol 1996; 103:319.</a></li><li><a class="nounderline abstract_t">van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med (Maywood) 2001; 226:243.</a></li><li><a class="nounderline abstract_t">Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995; 172:1436.</a></li><li><a class="nounderline abstract_t">Yang Y, Chen J, Wang B, et al. Association between MTHFR C677T polymorphism and neural tube defect risks: A comprehensive evaluation in three groups of NTD patients, mothers, and fathers. Birth Defects Res A Clin Mol Teratol 2015; 103:488.</a></li><li><a class="nounderline abstract_t">Windham GC, Bjerkedal T, Sever LE. The association of twinning and neural tube defects: studies in Los Angeles, California, and Norway. Acta Genet Med Gemellol (Roma) 1982; 31:165.</a></li><li><a class="nounderline abstract_t">Ross ME, Mason CE, Finnell RH. Genomic approaches to the assessment of human spina bifida risk. Birth Defects Res 2017; 109:120.</a></li><li><a class="nounderline abstract_t">Deak KL, Siegel DG, George TM, et al. Further evidence for a maternal genetic effect and a sex-influenced effect contributing to risk for human neural tube defects. Birth Defects Res A Clin Mol Teratol 2008; 82:662.</a></li><li><a class="nounderline abstract_t">Wilson RD, O'Connor DL. Guideline No. 427: Folic Acid and Multivitamin Supplementation for Prevention of Folic Acid-Sensitive Congenital Anomalies. J Obstet Gynaecol Can 2022; 44:707.</a></li><li><a class="nounderline abstract_t">Li DK, Janevic T, Odouli R, Liu L. Hot tub use during pregnancy and the risk of miscarriage. Am J Epidemiol 2003; 158:931.</a></li><li><a class="nounderline abstract_t">Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol 2006; 76:507.</a></li><li><a class="nounderline abstract_t">Mohan Dass NL, Botto LD, Tinker SC, et al. Associations between maternal reports of periconceptional fever from miscellaneous causes and structural birth defects. Birth Defects Res 2022; 114:885.</a></li><li><a class="nounderline abstract_t">Dreier JW, Andersen AM, Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. Pediatrics 2014; 133:e674.</a></li><li><a class="nounderline abstract_t">Edwards MJ. Hyperthermia as a teratogen: a review of experimental studies and their clinical significance. Teratog Carcinog Mutagen 1986; 6:563.</a></li><li><a class="nounderline abstract_t">Graham JM Jr, Edwards MJ, Edwards MJ. Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans. Teratology 1998; 58:209.</a></li><li><a class="nounderline abstract_t">Kerr SM, Parker SE, Mitchell AA, et al. Periconceptional maternal fever, folic acid intake, and the risk for neural tube defects. Ann Epidemiol 2017; 27:777.</a></li><li><a class="nounderline abstract_t">Waller DK, Hashmi SS, Hoyt AT, et al. Maternal report of fever from cold or flu during early pregnancy and the risk for noncardiac birth defects, National Birth Defects Prevention Study, 1997-2011. Birth Defects Res 2018; 110:342.</a></li><li><a class="nounderline abstract_t">Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115:109.</a></li><li><a class="nounderline abstract_t">Sukanya S, Bay BH, Tay SS, Dheen ST. Frontiers in research on maternal diabetes-induced neural tube defects: Past, present and future. World J Diabetes 2012; 3:196.</a></li><li><a class="nounderline abstract_t">Gabbay-Benziv R, Reece EA, Wang F, Yang P. Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis. World J Diabetes 2015; 6:481.</a></li><li><a class="nounderline abstract_t">Garne E, Loane M, Dolk H, et al. Spectrum of congenital anomalies in pregnancies with pregestational diabetes. Birth Defects Res A Clin Mol Teratol 2012; 94:134.</a></li><li><a class="nounderline abstract_t">Loeken MR. Current perspectives on the causes of neural tube defects resulting from diabetic pregnancy. Am J Med Genet C Semin Med Genet 2005; 135C:77.</a></li><li><a class="nounderline abstract_t">Racusin D, Stevens B, Campbell G, Aagaard KM. Obesity and the risk and detection of fetal malformations. Semin Perinatol 2012; 36:213.</a></li><li><a class="nounderline abstract_t">Makelarski JA, Romitti PA, Rocheleau CM, et al. Maternal periconceptional occupational pesticide exposure and neural tube defects. Birth Defects Res A Clin Mol Teratol 2014; 100:877.</a></li><li><a class="nounderline abstract_t">Pettigrew SM, Bell EM, Van Zutphen AR, et al. Paternal and joint parental occupational pesticide exposure and spina bifida in the National Birth Defects Prevention Study, 1997 to 2002. Birth Defects Res A Clin Mol Teratol 2016; 106:963.</a></li><li><a class="nounderline abstract_t">Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Impact of Periconceptional Use of Nitrosatable Drugs on the Risk of Neural Tube Defects. Am J Epidemiol 2015; 182:675.</a></li><li><a class="nounderline abstract_t">Auffret M, Cottin J, Vial T, Cucherat M. Clomiphene citrate and neural tube defects: a meta-analysis of controlled observational studies. BJOG 2019; 126:1127.</a></li><li><a class="nounderline abstract_t">Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med 2019; 381:827.</a></li><li><a class="nounderline abstract_t">Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana. N Engl J Med 2019; 381:885.</a></li><li><a class="nounderline abstract_t">Reefhuis J, FitzHarris LF, Gray KM, et al. Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection - 15 Jurisdictions, 2013-2017. MMWR Morb Mortal Wkly Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Li K, Wahlqvist ML, Li D. Nutrition, One-Carbon Metabolism and Neural Tube Defects: A Review. Nutrients 2016; 8.</a></li><li><a class="nounderline abstract_t">Boyd PA, Devigan C, Khoshnood B, et al. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG 2008; 115:689.</a></li><li><a class="nounderline abstract_t">Wang ZP, Li H, Hao LZ, Zhao ZT. The effectiveness of prenatal serum biomarker screening for neural tube defects in second trimester pregnant women: a meta-analysis. Prenat Diagn 2009; 29:960.</a></li><li class="breakAll">Jorde LB, Carey JC, Bamshad MJ. Genetic testing and gene therapy. In: Medical Genetics, 5th ed, Elsevier, Philadelphia 2015.</li><li><a class="nounderline abstract_t">Practice Bulletin No. 187: Neural Tube Defects. Obstet Gynecol 2017; 130:e279.</a></li><li><a class="nounderline abstract_t">Driscoll DA, Gross SJ, Professional Practice Guidelines Committee. Screening for fetal aneuploidy and neural tube defects. Genet Med 2009; 11:818.</a></li><li><a class="nounderline abstract_t">Bartkute K, Balsyte D, Wisser J, Kurmanavicius J. Pregnancy outcomes regarding maternal serum AFP value in second trimester screening. J Perinat Med 2016.</a></li><li><a class="nounderline abstract_t">Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30:918.</a></li><li><a class="nounderline abstract_t">Norem CT, Schoen EJ, Walton DL, et al. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. Obstet Gynecol 2005; 106:747.</a></li><li><a class="nounderline abstract_t">Cameron M, Moran P. Prenatal screening and diagnosis of neural tube defects. Prenat Diagn 2009; 29:402.</a></li><li><a class="nounderline abstract_t">Bredaki FE, Poon LC, Birdir C, et al. First-trimester screening for neural tube defects using alpha-fetoprotein. Fetal Diagn Ther 2012; 31:109.</a></li><li><a class="nounderline abstract_t">Aitken DA, McCaw G, Crossley JA, et al. First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. Prenat Diagn 1993; 13:681.</a></li><li><a class="nounderline abstract_t">Bernard JP, Cuckle HS, Bernard MA, et al. Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers. Am J Obstet Gynecol 2013; 209:223.e1.</a></li><li><a class="nounderline abstract_t">Sebire NJ, Spencer K, Noble PL, et al. Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1997; 104:849.</a></li><li><a class="nounderline abstract_t">Spencer K, Khalil A, Brown L, et al. First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida. Prenat Diagn 2014; 34:168.</a></li><li><a class="nounderline abstract_t">Wald N, Cuckle H, Boreham J, et al. The effect of maternal weight on maternal serum alpha-fetoprotein levels. Br J Obstet Gynaecol 1981; 88:1094.</a></li><li><a class="nounderline abstract_t">Thornburg LL, Knight KM, Peterson CJ, et al. Maternal serum alpha-fetoprotein values in type 1 and type 2 diabetic patients. Am J Obstet Gynecol 2008; 199:135.e1.</a></li><li><a class="nounderline abstract_t">Reichler A, Hume RF Jr, Drugan A, et al. Risk of anomalies as a function of level of elevated maternal serum alpha-fetoprotein. Am J Obstet Gynecol 1994; 171:1052.</a></li><li><a class="nounderline abstract_t">Morrow RJ, Whittle MJ, McNay MB, et al. Prenatal diagnosis and management of anterior abdominal wall defects in the west of Scotland. Prenat Diagn 1993; 13:111.</a></li><li class="breakAll">http://www.acmg.net/pages/acmg_activities/stds-2002/ontd.htm (Accessed on January 18, 2017).</li><li><a class="nounderline abstract_t">Burns RN, Kolarova T, Katz R, et al. Reconsidering Race Adjustment in Prenatal Alpha-Fetoprotein Screening. Obstet Gynecol 2023; 141:438.</a></li><li><a class="nounderline abstract_t">Palomaki GE, Bupp C, Gregg AR, et al. Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020; 22:462.</a></li><li class="breakAll">College of American Pathologists. Chemistry and toxicology checklist. CAP accreditation program. Accessed August 8,
2022. http://appsuite.cap.org/appsuite/learning/LAP/TLTM/ resources/checklists/2020/cl-chm.pdf.</li><li><a class="nounderline abstract_t">Huerta-Enochian G, Katz V, Erfurth S. The association of abnormal alpha-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol 2001; 184:1549.</a></li><li><a class="nounderline abstract_t">Gotha L, Pruthi V, Abbasi N, et al. Fetal spina bifida: What we tell the parents. Prenat Diagn 2020; 40:1499.</a></li><li><a class="nounderline abstract_t">Di Mascio D, Greco F, Rizzo G, et al. Diagnostic accuracy of prenatal ultrasound in identifying the level of the lesion in fetuses with open spina bifida: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2021; 100:210.</a></li><li><a class="nounderline abstract_t">Stoll C, Dott B, Alembik Y, Roth MP. Associated malformations among infants with neural tube defects. Am J Med Genet A 2011; 155A:565.</a></li><li><a class="nounderline abstract_t">Kennedy D, Chitayat D, Winsor EJ, et al. Prenatally diagnosed neural tube defects: ultrasound, chromosome, and autopsy or postnatal findings in 212 cases. Am J Med Genet 1998; 77:317.</a></li><li><a class="nounderline abstract_t">Hume RF Jr, Drugan A, Reichler A, et al. Aneuploidy among prenatally detected neural tube defects. Am J Med Genet 1996; 61:171.</a></li><li><a class="nounderline abstract_t">Sepulveda W, Corral E, Ayala C, et al. Chromosomal abnormalities in fetuses with open neural tube defects: prenatal identification with ultrasound. Ultrasound Obstet Gynecol 2004; 23:352.</a></li><li><a class="nounderline abstract_t">Drugan A, Johnson MP, Dvorin E, et al. Aneuploidy with neural tube defects: another reason for complete evaluation in patients with suspected ultrasound anomalies or elevated maternal serum alpha-fetoprotein. Fetal Ther 1989; 4:88.</a></li><li><a class="nounderline abstract_t">Warner AA, Pettenati MJ, Burton BK. Risk of fetal chromosomal anomalies in patients with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1990; 75:64.</a></li><li><a class="nounderline abstract_t">Ekin A, Gezer C, Taner CE, et al. Chromosomal and structural anomalies in fetuses with open neural tube defects. J Obstet Gynaecol 2014; 34:156.</a></li><li><a class="nounderline abstract_t">Kanit H, Özkan AA, Öner SR, et al. Chromosomal abnormalities in fetuses with ultrasonographically detected neural tube defects. Clin Dysmorphol 2011; 20:190.</a></li><li><a class="nounderline abstract_t">Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet 2019; 393:758.</a></li><li><a class="nounderline abstract_t">Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. Lancet 2019; 393:747.</a></li><li><a class="nounderline abstract_t">Rossi AC, Prefumo F. Additional value of fetal magnetic resonance imaging in the prenatal diagnosis of central nervous system anomalies: a systematic review of the literature. Ultrasound Obstet Gynecol 2014; 44:388.</a></li><li><a class="nounderline abstract_t">Saleem SN, Said AH, Abdel-Raouf M, et al. Fetal MRI in the evaluation of fetuses referred for sonographically suspected neural tube defects (NTDs): impact on diagnosis and management decision. Neuroradiology 2009; 51:761.</a></li><li><a class="nounderline abstract_t">Wilson RD, SOGC GENETICS COMMITTEE, SPECIAL CONTRIBUTOR. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can 2014; 36:927.</a></li><li><a class="nounderline abstract_t">Frey HA, Odibo AO, Dicke JM, et al. Stillbirth risk among fetuses with ultrasound-detected isolated congenital anomalies. Obstet Gynecol 2014; 124:91.</a></li><li><a class="nounderline abstract_t">Andonotopo W, Kurjak A, Kosuta MI. Behavior of an anencephalic fetus studied by 4D sonography. J Matern Fetal Neonatal Med 2005; 17:165.</a></li><li><a class="nounderline abstract_t">Kurauchi O, Ohno Y, Furugori K, et al. Comparative study of fetal behaviour in a case of monozygotic twins, one being anencephalic. Gynecol Obstet Invest 1996; 42:209.</a></li><li><a class="nounderline abstract_t">Kurauchi O, Ohno Y, Mizutani S, Tomoda Y. Longitudinal monitoring of fetal behavior in twins when one is anencephalic. Obstet Gynecol 1995; 86:672.</a></li><li><a class="nounderline abstract_t">Warsof SL, Abramowicz JS, Sayegh SK, Levy DL. Lower limb movements and urologic function in fetuses with neural tube and other central nervous system defects. Fetal Ther 1988; 3:129.</a></li><li><a class="nounderline abstract_t">Visser GH, Laurini RN, de Vries JI, et al. Abnormal motor behaviour in anencephalic fetuses. Early Hum Dev 1985; 12:173.</a></li><li><a class="nounderline abstract_t">van Heteren CF, Boekkooi PF, Jongsma HW, Nijhuis JG. Responses to vibroacoustic stimulation in a fetus with an encephalocele compared to responses of normal fetuses. J Perinat Med 2000; 28:306.</a></li><li><a class="nounderline abstract_t">Ohel G, Simon A, Linder N, Mor-Yosef S. Anencephaly and the nature of fetal response to vibroacoustic stimulation. Am J Perinatol 1986; 3:345.</a></li><li><a class="nounderline abstract_t">Rendeli C, Nucera E, Ausili E, et al. Latex sensitisation and allergy in children with myelomeningocele. Childs Nerv Syst 2006; 22:28.</a></li><li><a class="nounderline abstract_t">Cremer R, Kleine-Diepenbruck U, Hoppe A, Bläker F. Latex allergy in spina bifida patients--prevention by primary prophylaxis. Allergy 1998; 53:709.</a></li><li><a class="nounderline abstract_t">Luthy DA, Wardinsky T, Shurtleff DB, et al. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. N Engl J Med 1991; 324:662.</a></li><li><a class="nounderline abstract_t">Tolcher MC, Shazly SA, Shamshirsaz AA, et al. Neurological outcomes by mode of delivery for fetuses with open neural tube defects: a systematic review and meta-analysis. BJOG 2019; 126:322.</a></li><li><a class="nounderline abstract_t">Benjamin RH, Lopez A, Mitchell LE, et al. Mortality by mode of delivery among infants with spina bifida in Texas. Birth Defects Res 2019; 111:1543.</a></li><li><a class="nounderline abstract_t">Obeidi N, Russell N, Higgins JR, O'Donoghue K. The natural history of anencephaly. Prenat Diagn 2010; 30:357.</a></li><li><a class="nounderline abstract_t">Jaquier M, Klein A, Boltshauser E. Spontaneous pregnancy outcome after prenatal diagnosis of anencephaly. BJOG 2006; 113:951.</a></li><li><a class="nounderline abstract_t">Gatta LA, Akinshola TF, Santoli CMA, et al. Maternal morbidity in pregnancies affected by anencephaly. Am J Obstet Gynecol 2023; 229:345.</a></li><li><a class="nounderline abstract_t">Milic AB, Adamsons K. The relationship between anencephaly and prolonged pregnancy. J Obstet Gynaecol Br Commonw 1969; 76:102.</a></li><li><a class="nounderline abstract_t">Osathanondh R, Donnenfeld AE, Frigoletto FD Jr, et al. Induction of labor with anencephalic fetus. Obstet Gynecol 1980; 56:655.</a></li><li><a class="nounderline abstract_t">Thiery M, Parewijck W, Decoster JM. Prostaglandins for the management of anencephalic pregnancy. Prostaglandins 1981; 21:207.</a></li><li><a class="nounderline abstract_t">Cowchock S, Ainbender E, Prescott G, et al. The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet 1980; 5:309.</a></li><li><a class="nounderline abstract_t">Toriello HV, Higgins JV. Occurrence of neural tube defects among first-, second-, and third-degree relatives of probands: results of a United States study. Am J Med Genet 1983; 15:601.</a></li><li><a class="nounderline abstract_t">Seller MJ. Recurrence risks for neural tube defects in a genetic counseling clinic population. J Med Genet 1981; 18:245.</a></li><li><a class="nounderline abstract_t">Czeizel A, Métneki J. Recurrence risk after neural tube defects in a genetic counselling clinic. J Med Genet 1984; 21:413.</a></li><li><a class="nounderline abstract_t">Koch M, Fuhrmann W. Sibs of probands with neural tube defects--a study in the Federal Republic of Germany. Hum Genet 1985; 70:74.</a></li><li class="breakAll">Nussbaum R, McInnes RR, Willard, HF. Genetics of disorders with complex inheritance. In: Thompson &amp; Thompson Genetics in Medicine, 6th ed, WB Saunders Co, Philadelphia 2001. p.289.</li><li><a class="nounderline abstract_t">MacCarthy PA, Dalrymple IJ, Duignan NM, et al. Recurrence rates of neural tube defects in Dublin maternity hospitals. Ir Med J 1983; 76:78.</a></li><li><a class="nounderline abstract_t">Medical Task Force on Anencephaly. The infant with anencephaly. N Engl J Med 1990; 322:669.</a></li></ol></div><div id="topicVersionRevision">Topic 460 Version 79.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27064786" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Describing the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590678" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Updated estimates of neural tube defects prevented by mandatory folic Acid fortification - United States, 1995-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097374" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30569547" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Teratology society position statement on surveillance and prevalence estimation of neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34976673" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Maternal folic acid and multivitamin supplementation: International clinical evidence with considerations for the prevention of folate-sensitive birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25032496" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23790957" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neural tube defects: recent advances, unsolved questions, and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15151734" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of fetal exposure to folic acid antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384952" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neural tube defects in relation to use of folic acid antagonists during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621443" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26562127" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Global Birth Prevalence of Spina Bifida by Folic Acid Fortification Status: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33338998" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Folate fortification and supplementation in prevention of folate-sensitive neural tube defects: a systematic review of policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096168" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Folic acid antagonists during pregnancy and the risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605127" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Blood folic acid and vitamin B12 in relation to neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11368417" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Folate, homocysteine and neural tube defects: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755050" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neural tube defects and elevated homocysteine levels in amniotic fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25808073" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association between MTHFR C677T polymorphism and neural tube defect risks: A comprehensive evaluation in three groups of NTD patients, mothers, and fathers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6763438" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The association of twinning and neural tube defects: studies in Los Angeles, California, and Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27883265" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genomic approaches to the assessment of human spina bifida risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937341" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Further evidence for a maternal genetic effect and a sex-influenced effect contributing to risk for human neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35691683" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Guideline No. 427: Folic Acid and Multivitamin Supplementation for Prevention of Folic Acid-Sensitive Congenital Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607798" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hot tub use during pregnancy and the risk of miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16933304" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Review: Hyperthermia and fever during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35932236" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Associations between maternal reports of periconceptional fever from miscellaneous causes and structural birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24567014" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2881371" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hyperthermia as a teratogen: a review of experimental studies and their clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9839360" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133009" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Periconceptional maternal fever, folic acid intake, and the risk for neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29094488" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Maternal report of fever from cold or flu during early pregnancy and the risk for noncardiac birth defects, National Birth Defects Prevention Study, 1997-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20027042" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301121" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Frontiers in research on maternal diabetes-induced neural tube defects: Past, present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25897357" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371321" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Spectrum of congenital anomalies in pregnancies with pregestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800853" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Current perspectives on the causes of neural tube defects resulting from diabetic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22713503" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Obesity and the risk and detection of fetal malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25124525" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Maternal periconceptional occupational pesticide exposure and neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27891778" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Paternal and joint parental occupational pesticide exposure and spina bifida in the National Birth Defects Prevention Study, 1997 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26424074" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of Periconceptional Use of Nitrosatable Drugs on the Risk of Neural Tube Defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31006176" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clomiphene citrate and neural tube defects: a meta-analysis of controlled observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329379" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329378" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917782" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection - 15 Jurisdictions, 2013-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27886045" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nutrition, One-Carbon Metabolism and Neural Tube Defects: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410651" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609892" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effectiveness of prenatal serum biomarker screening for neural tube defects in second trimester pregnant women: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609892" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effectiveness of prenatal serum biomarker screening for neural tube defects in second trimester pregnant women: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189693" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Practice Bulletin No. 187: Neural Tube Defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915395" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Screening for fetal aneuploidy and neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771626" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pregnancy outcomes regarding maternal serum AFP value in second trimester screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038077" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Obstetrical complications associated with abnormal maternal serum markers analytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199631" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19301349" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prenatal screening and diagnosis of neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377693" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : First-trimester screening for neural tube defects using alpha-fetoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8284287" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23673229" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236655" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24226839" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6170309" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effect of maternal weight on maternal serum alpha-fetoprotein levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18455133" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Maternal serum alpha-fetoprotein values in type 1 and type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524324" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk of anomalies as a function of level of elevated maternal serum alpha-fetoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7681976" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prenatal diagnosis and management of anterior abdominal wall defects in the west of Scotland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7681976" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prenatal diagnosis and management of anterior abdominal wall defects in the west of Scotland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735409" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reconsidering Race Adjustment in Prenatal Alpha-Fetoprotein Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31700163" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31700163" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408879" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The association of abnormal alpha-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32692418" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fetal spina bifida: What we tell the parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979219" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnostic accuracy of prenatal ultrasound in identifying the level of the lesion in fetuses with open spina bifida: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21337695" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Associated malformations among infants with neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600743" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prenatally diagnosed neural tube defects: ultrasound, chromosome, and autopsy or postnatal findings in 212 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8669447" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Aneuploidy among prenatally detected neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065184" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Chromosomal abnormalities in fetuses with open neural tube defects: prenatal identification with ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2484814" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Aneuploidy with neural tube defects: another reason for complete evaluation in patients with suspected ultrasound anomalies or elevated maternal serum alpha-fetoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688649" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk of fetal chromosomal anomalies in patients with elevated maternal serum alpha-fetoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24456437" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chromosomal and structural anomalies in fetuses with open neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21709547" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chromosomal abnormalities in fetuses with ultrasonographically detected neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712878" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712880" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890732" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Additional value of fetal magnetic resonance imaging in the prenatal diagnosis of central nervous system anomalies: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19554321" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fetal MRI in the evaluation of fetuses referred for sonographically suspected neural tube defects (NTDs): impact on diagnosis and management decision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375307" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24901272" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Stillbirth risk among fetuses with ultrasound-detected isolated congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076628" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Behavior of an anencephalic fetus studied by 4D sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938477" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Comparative study of fetal behaviour in a case of monozygotic twins, one being anencephalic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675409" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Longitudinal monitoring of fetal behavior in twins when one is anencephalic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3077584" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Lower limb movements and urologic function in fetuses with neural tube and other central nervous system defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905349" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Abnormal motor behaviour in anencephalic fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11031701" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Responses to vibroacoustic stimulation in a fetus with an encephalocele compared to responses of normal fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3755921" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Anencephaly and the nature of fetal response to vibroacoustic stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703967" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Latex sensitisation and allergy in children with myelomeningocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9700041" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Latex allergy in spina bifida patients--prevention by primary prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994249" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29924919" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Neurological outcomes by mode of delivery for fetuses with open neural tube defects: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31642615" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Mortality by mode of delivery among infants with spina bifida in Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20198650" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The natural history of anencephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827827" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Spontaneous pregnancy outcome after prenatal diagnosis of anencephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37182756" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Maternal morbidity in pregnancies affected by anencephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4885486" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The relationship between anencephaly and prolonged pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7432739" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Induction of labor with anencephalic fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7221011" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prostaglandins for the management of anencephalic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7405962" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The recurrence risk for neural tube defects in the United States: a collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614048" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Occurrence of neural tube defects among first-, second-, and third-degree relatives of probands: results of a United States study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7277415" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Recurrence risks for neural tube defects in a genetic counseling clinic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6512828" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Recurrence risk after neural tube defects in a genetic counselling clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873392" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Sibs of probands with neural tube defects--a study in the Federal Republic of Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873392" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Sibs of probands with neural tube defects--a study in the Federal Republic of Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6341309" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Recurrence rates of neural tube defects in Dublin maternity hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2406598" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The infant with anencephaly.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
